The potent carcinogenicity of dibenzo [a,/]pyrene in mouse skin is associated with an inflammation unique among polycyclic aromatic hydrocarbons and expressed as erythema. The time course of erythema and the associated histological events in the skin of female SENCAR mice were determined after a single application of 6.25-200 nmol dibenzo[a,/]pyrene or selected metabolites. Dibenzo [a,/]pyrene and dibenzo[a,/]pyrene-ll,12-dihydrodiol, precursor to the bay-region diol epoxide, induced an erythema first present 5-6 days after treatment Dibenzo[a,/]pyrene-8,9-dihydrodiol and other dibenzo[a,/]pyrene metabolites, however, did not induce erythema. These findings suggest a central role for the bayregion diol epoxide in the induction of the observed inflammation. The intensity and duration of erythema were dose-dependent, whereas the delayed appearance of erythema was constant and dose-independent. These results suggest induction of an immune hypersensitivity by dibenzo[a,/]pyrene and its 11,12-dihydrodiol. Histological changes in the skin were consistent with a contact hypersensitivity reaction and included, in association with erythema, epidermal hyperplasia and the presence of mononuclear leukocytes in the dermis. Animals were tested for dibenzo[a,/]-pyrene-induced contact hypersensitivity. Female SENCAR mice were treated with a single dermal application of dibenzo[a,/]pyrene or 7,12-dimethylbenz[a]anthracene. Five days later, the animals were challenged with a single application of dibenzo[a,/]pyrene or 7,12-dimethylbenz [a]anthracene to the ear pinna. Ear swelling exhibited features of a contact hypersensitivity reaction, including (1) delayed appearance after challenge, (2) noninducibility in animals not previously exposed to chemical sensitizer, and (3) chemical specificity. The results suggest that dibenzo[a,/]pyrene induces, via its bay-region diol epoxide, a contact hypersensitivity reaction that may promote tumor development and thereby enhance carcinogenic potency. V 1997 Sod«y of Toiteology.
Chemical carcinogenesis in mouse skin is a multistage process that includes initiation and promotion (DiGiovanni, 1992) . The first stage, initiation, involves reaction of an electrophilic species with DNA, producing critical mutations. Expression of the genomic alteration leading to development of tumors requires promotion by repeated application of the carcinogen or of a noncarcinogenic promoting agent, e.g., 12-0-tetradecanoylphorbol-13-acetate (TPA) 2 (Van Duuren, 1969) . Promotion is viewed as stimulating clonal expansion of initiated cells, producing papillomas and, ultimately, carcinomas. Studies of TPA and other promoting agents support the view that a sustained increase in epidermal cell proliferation, of appropriate magnitude, is sufficient for tumor promotion (DiGiovanni, 1992) . In addition, promoter-induced inflammation may be fundamental to carcinogenesis by stimulating epidermal cell proliferation and hyperplasia (Aldaz et al., 1985) .
Though a wide variety of chemicals exhibit tumor-promoting activity (DiGiovanni, 1992) , very little is known about the promoting properties of complete carcinogens. 7-Bromomethyibenz [a] anthracene is a complete carcinogen that has weak initiating activity, but has unusually potent tumor-promoting activity. Consequently, it has been possible to separate these two functions experimentally and to demonstrate that promotion is a significant determinant of carcinogenic potency (Scribner and Scribner, 1980) . In an attempt to develop a model of promotion by benzo [a] pyrene (BP), Albert et al. (1991) sought evidence of tumor promotion by high doses of this compound applied repeatedly to mouse skin. They found corresponding dose-response profiles for epidermal damage, epidermal hyperplasia, dermal inflam-mation, and tumor incidence, suggesting injury-induced promotion. They concluded, however, that the observed promotion may have been a high-dose phenomenon and lower doses of BP may not induce injury and regenerative hyperplasia.
Recently, dibenzo [a,/] pyrene (DB[a,/]P) was shown to be the most potent carcinogenic polycyclic aromatic hydrocarbon (PAH) in mouse skin and rat mammary gland (Cavalieri et al., 1991; Gill et al, 1994; Higginbotham et al., 1993; LaVoie et al., 1993) . Of particular interest is the observation that the carcinogenic potency of DB[a,/]P in mouse skin is associated with an inflammation unique among PAH and expressed as dermal erythema. In initiation-promotion studies, doses of 20 or 100 nmol DB[a,/]P produced intense inflammation and dermal toxicity that interfered with induction of tumors (Higginbotham et al., 1993) . Tumor production was inversely proportional to dose. In contrast, at low doses (0.25 to 4 nmol), inflammation was mild and tumor production was directly proportional to dose. In both repeated and single-application studies (Cavalieri et al., 1991; Higginbotham et al., 1993) , DB[a,/]P-induced inflammation was associated with development of skin tumors. For example, a single dose of 100 nmol DB[a,/]P, in the absence of treatment with any tumor promoter, produced both papillomas and squamous cell carcinomas in association with an early dermal erythema. The extreme toxicity produced by similar doses of DB[a,/]P in initiation-promotion studies and characterized by extensive ulceration and epidermal replacement was not observed.
These observations led us to propose that the inflammatory response induced by DB[a,/]P promotes tumor development and contributes significantly to its carcinogenic potency. Thus, DB[a,/]P offers a unique opportunity to study promotion by a complete carcinogen. Knowledge of the mechanism of DB[a,/]P-induced promotion will provide a model for other carcinogenic PAH. In the present study, the time course and concentration dependency of erythema have been determined, as well as histological changes in mouse skin after a single application of DB[a,/]P or selected metabolites. These studies in conjunction with immunological testing suggest that the observed erythema may be an expression of contact hypersensitivity.
MATERIALS AND METHODS

Chemicals.
DB[a,/]P (mp 161-162°C) and 7,12-dimethylbenz[a]-anthracene (DMBA) were available in our laboratory. DB[a,/]P-l 1,12-dihydrodiol (DB[a,/]P-l 1,12-diol), (±)-anri-DB[a,/]P diol epoxide (an/i-DB[a,/]PDE), and (±)-syn-DB [a,l] P diol epoxide (ryn-DB[a,/]PDE) were obtained from the National Cancer Institute Chemical Carcinogen Repository (Chemsyn Science Laboratories, Lenexa, KS) (Gill et al, 1994) . DB[a,/]P-8,9-dihydrodiol (DB[a,/]P-8,9-diol) was prepared by NADPHsupported metabolism of DB[a,/]P with 3-methylcholanthrene-induced rat liver microsomes, as previously described (Devanesan et at, 1990) . Purity was determined by analytical HPLC and found to be >99% for all compounds. Caution: DMBA, DB[a,f)P, and its metabolites are hazardous chemicals and were handled according to NTH guidelines (NTH, 1981) . Animals. Six-week-old female SENCAR mice were purchased from the NCI Frederick Cancer Center (Frederick, MD) and Harlan Laboratories (Indianapolis, IN). Because NCI mice were temporarily unavailable, some of the work was completed with Harlan mice. The animals were acclimated to our animal facility for 2 weeks, then placed on experiment at 8 weeks of age.
Experimental procedures. Groups of 10-20 mice were treated with a single application of PAH in 100 /i] of acetone on the shaved skin of the back. Controls were treated with a single application of acetone alone. Subsequently, dermal erythema was charted daily as follows: "0," none; "1," definitive but weak; "2," moderate; and "3," intense. A daily score for each treatment group was computed as the sum of the products of each erythema score and the percentage of mice exhibiting the score. On selected days, two to five animals from each treatment group were sacrificed by CO 2 asphyxiation and skin samples were taken for histological evaluation. The skin samples were fixed in 10% neutral-buffered Formalin solution. Four strips were cut from each skin sample. These were embedded in paraffin, sectioned at 5 fj.m, and stained with eosin and hematoxylin.
Contact hypersensitivity was induced in groups of five or six mice by treatment with a single application of DB[a,/]P or DMBA in 100 ^tl acetone to the shaved skin of the back. Controls were treated with acetone alone. Contact hypersensitivity reactions expressed as ear swelling (Asherson and Ptak, 1968) were elicited by a single application of DB[a,/]P or DMBA in 20 fi\ of acetone to the dorsum of the left ear pinna. Acetone alone was applied to the right ear. Animals were lightly anesthetized with ether and the thickness of both the left and right ear pinna was measured to 0.0001 in. with an engineer's micrometer (Mitutoyo, Tokyo, Japan). Ear thicknesses were measured 1 day prior to chemical treatment of the ears, then daily for 9 days after chemical treatment The mean of the differences between the left and right ear thicknesses was determined for each group of five to six mice. The ear-swelling reaction was expressed as the increment of this group mean on each day, after chemical treatment, in reference to the group mean prior to chemical treatment.
RESULTS
Time course of dermal erythema in mouse skin after a single application of DB [a, l\P or DB[a, . Treatment of mouse skin with a single application of DB[a,/]P or DB[a,/]P-l 1,12-dihydrodiol, precursor to the bay-region diol epoxide ( Fig. 1) , induced an erythema that was first apparent 5 to 6 days after treatment and reached maximum intensity by 7 to 10 days (Fig. 2 ). This early time course was characteristic and did not change with increasing doses of the inducers. In contrast, both the intensity and duration of the erythema were dose-dependent. The erythema induced by 50 or 200 nmol of DB[a,/]P (or DB[a,/]P-11,12-dihydrodiol) subsided by Day 14 or 21, respectively (Fig. 2B ). Responses were more protracted in experiment 1 ( Fig. 2A ) in comparison with experiment 2 (Fig. 2B ). These differences may have been due to the use of NCI SENCAR mice in experiment 1 and Harlan SENCAR mice in experiment 2. Application of DB[a,/]P-8,9-dihydrodiol, the K-region dihydrodiol, or syn-or anti-DB [a,[] PDE ( Fig. 1) did not induce an erythema at the highest dose tested (200 nmol). Female SENCAR mice (NCI) were treated once on the shaved skin of the back with PAH in acetone. Dermal erythema was scored daily, beginning 1 day after treatment, as follows: 0, none; 1, definitive but weak; 2, moderate; and 3, intense. Each data point represents the cumulative dermal erythema of a treatment group and was computed as the sum of the products of die erythema score and the percentage of animals exhibiting the score. (B) Experiment 2. Female SENCAR mice (Harlan) were treated on the skin as in A. Dermal erythema was scored daily, beginning 1 day after treatment Each data point represents the cumulative dermal erythema of a treatment group as described in A. [a, l\P or DB[a, . Marked alterations were seen in the epidermis 2 days after a single application of 200 nmol DB[a,/]P or DB [a,/]P-11,12-dihydrodiol to the shaved skin of the back. The thickness of the interfollicular epidermis was increased by enlargement of existing keratinocytes (Figs. 3A and 3B) , producing an apparent increase in the number of epidermal cell layers (Raick, 1973) . Most of the keratinocytes were reactive, as indicated by enlarged nuclei with prominent nucleoli and increased cytoplasmic volume. Reactive cells were present at all levels of the epidermis on Days 2 through 4 (Fig. 3B) , but occupied only the upper one-third to onehalf of the epidermis on Days 5 through 7 (Fig. 3C) . Epidermal cell damage, evidenced by perinuclear vacuolation associated with nuclear pycnosis, was present on Days 2 through 4 (Fig. 3B) . During this period, small numbers of necrotic keratinocytes, characterized by cytoplasmic eosinophilia and nuclear pycnosis, were scattered throughout the epidermis. These features of epidermal damage were greatly attenuated on Days 5 through 7 (Fig. 3C) .
Light microscopic pathology of mouse skin treated with a single application of DB
Beginning on Day 5, the epidermis assumed a distinctively hyperplastic character, which persisted through the remainder of the observation period (Fig. 3C) . Cells, present in the lower one-third to one-half of the epidermis, were oriented with their long axes perpendicular to the dermal/epidermal interface and exhibited a regular platelike configuration. Dark cells, characteri2ed by deep basophilia of the nucleus and cytoplasm, were distinctive features of the observed hyperplasia. The platelike configuration of the epidermal hyperplasia was accented by a prominent intercellular edema apparent as unstained cell boundaries (Fig. 3C) . Epidermal hyperplasia was accompanied by hyperkeratosis, i.e., increased thickness of the outermost cornified layer of the epidermis. Except for an occasional focal ulceration (Fig.  3D) , containing a large number of polymorphonuclear leukocytes (PMNL), leukocytes were not seen in the epidermis. Ulceration was a minimal and inconsistent feature of the response to a single dermal application of DB[a,/]P or DB[a,/]P-l 1,12-dihydrodiol. These focal lesions comprised at best a few percent of the treated area and resolved rapidly.
The dermis also displayed marked alterations 2 days after a single application of 200 nmol DB[a,/]P or DB[a,/]P-11,12-dihydrodiol. At this time, the dermis was infiltrated with inflammatory cells consisting primarily of PMNL. An inflammatory cell infiltrate was present in the dermis throughout the observation period (Fig. 3 ) and was maximal 6 days after treatment of the skin. Leukocytic infiltration of the subcutaneous connective tissue (SCT) was apparent on Day 5 and reached a maximum by Day 6, in association with progression of leukocytic infiltration of the dermis. The inflammatory cell infiltrate shifted from predominantly PMNL, on Day 2, to a mixed infiltrate consisting of approximately equal numbers of PMNL and mononuclear leuko- (Fig. 3C) .
Determination of contact hypersensitivity induced by application ofDB[a,l\P to mouse skin. Characteristics of the erythema induced by DB[a,/]P and DB[a,/]P-ll,12-dihydrodiol were consistent with an adaptive immune response, i.e., induction of contact hypersensitivity. These characteristics included (1) a consistent delay in the appearance of the erythema for 5 to 6 days after skin treatment, independent of the dose of the inducer and the intensity of the erythema; and (2) a sharp rise to maximal erythema with the onset of this reaction. On this basis, DB[a,/]P-treated mice were evaluated for contact hypersensitivity expressed as an earswelling reaction to a challenge with DB[a,/]P. In the first experiment, groups of SENCAR mice were initiated on the shaved skin of the back with a single application of 100 nmol DB[a,/]P in acetone. Control mice were treated with a single application of acetone. Five days later, the animals were challenged with an application of 20, 40, or 80 nmol DB[a,/]P in acetone to the dorsum of the left ear. Acetone alone was applied to the right ear. Three days after ear challenge, swelling of the ear pinna was apparent among the DB[a,/]P-initiated mice, but not among those animals initially treated with acetone (Fig. 4) . By Day 4, the degree of ear swelling was marked and nearly maximal among the DB[a,/]P-initiated mice challenged with 80 nmol DB[a,/]P, but was insignificant among the acetone-initiated animals challenged with the same dose of DB[a,/]P. The intensity of the ear-swelling reaction was proportional to the challenge dose and was prominent for the remainder of the 9-day observation period. Five to 6 days after ear challenge, swelling of the ear pinna was apparent among the acetone-initiated mice (Fig. 4) . The time course of this reaction was the same as that seen for dermal erythema after a single application of DB[a,/]P or DB [a,/]P-11,12-dihydrodiol to the shaved skin of the back (Fig. 2) . The degree of this ear-swelling reaction was dose-dependent, as was dermal erythema.
In a second experiment, mice were initiated on the shaved skin of the back with a single application of 200 or 400 nmol DB[a,/]P or with 200 or 400 nmol DMBA, a carcinogen known to induce contact hypersensitivity in mice (Klemme et al., 1987) . Controls were treated with acetone alone. Five days later, the animals were challenged with a single application of 80 nmol DB[a,/]P in acetone to the dorsum of the left ear. Among those animals initiated with DB[a,/]P, marked swelling of the ear pinna was apparent 3 days after challenge and was intensive by Day 4 (Fig. 5) . In the same period, no significant changes were seen among those animals initiated with DMBA or acetone and challenged with DB[a,/]P (Fig. 5) or among animals initiated with DB[a,/]P and challenged with DMBA (data not shown). Consistent with the first experiment (above), significant ear swelling was seen 5 and 7 days after DB[o,/]P challenge of DMBA-and acetone-initiated mice. DISCUSSION DB[a,/]P and DB[a,/]P-l 1,12-dihydrodiol, a precursor to the bay-region diol epoxide, were shown to be potent inducers of erythema in mouse skin. In contrast, DB[a,/]P-8,9-dihydrodiol, the K-region dihydrodiol, did not induce an erythema at the highest dose tested (200 nmol). These results suggest an essential contribution of the bay-region diol epoxide to DB[a,/]P-induced erythema in mouse skin. DB[a,/]-PDE is a reactive electrophile which covalently binds to proteins and nucleic acids in the cell. It is proposed that covalent binding of this epoxide to critical proteins in the cell, very likely in the endoplasmic reticulum (ER) where the epoxide is mainly formed, produces immunogenic complexes which, in turn, induce a specific immunity expressed as a contact hypersensitivity reaction (dermal erythema). A similar mechanism has been proposed for halothane-induced hepatitis (Kenna et al., 1987; Kenna et al, 1988) . In the rat model, halothane is metabolized by cytochrome P450 to a trifluoroacetyl halide which binds covalently to soluble ER proteins. Certain of these trifluoroacetylated proteins are highly immunogenic. The evidence strongly suggests that these newly immunogenic ER proteins (neoantigens) induce an immune response which produces fulminant hepatitis. These neoantigens persist in appreciable amounts for at least 1 week after a single exposure to halothane (Kenna et al., 1990) . Formation of persistent neoantigens may provide a mechanism by which a single dermal application of DB[a,/]P or DB [a,/]P-11,12-dihydrodiol both induces a contact hypersensitivity and elicits a contact hypersensitivity reaction, i.e., erythema. Our proposed mechanism is consistent with the inability of both syn-and anfJ-DB[a,/]PDE to induce an erythema in mouse skin. Direct application of DB[a,/]PDE to mouse skin is expected to produce adducts to an array of extracellular proteins and possibly plasma membrane and cytosolic proteins, with little or no binding to ER proteins essential to the genesis of potent neoantigens.
Comparison of the time course of DB\a,l\P-induced dermal erythema with induction of contact hypersensitivity to dermal sensitizers. The dermal erythema induced by a single application of DB[a,/]P or DB[a,/]P-ll,12-dihydrodiol to mouse skin occurred after a characteristic delay of 5 to 6 days, independently of the dose of the inducers or the intensity of the erythema (Fig. 2) . This uniform delay in the onset of erythema reproduced the time course of induction of contact hypersensitivity to skin sensitizers, including 1- fluoro-2,4-dinitrobenzene (DNFB), BP, and DMBA, suggesting an immune mechanism. A single topical application of DNFB, a potent skin sensitizer and tumor promoter (Bock et al, 1969) , to the ear of the guinea pig or mouse induces the appearance of antigen-activated lymphocytes in the draining auricular lymph nodes (Fjelde and Turk, 1965; Turk and Stone, 1963) . The number of these cells is maximal 4 to 5 days after DNFB exposure, 1 day prior to-the appearance of contact hypersensitivity. BP and DMBA induce a similar increase in activated lymphocytes in the draining lymph nodes 4 to 5 days after a single topical application (Bock et al, 1969) . More recently, both BP and DMBA have been shown to induce contact hypersensitivity in mice treated with a single dermal application of either carcinogen (Klemme et al, 1987) . Contact hypersensitivity, expressed as an earswelling reaction to a secondary challenge, was present 5 days after an initial exposure to the carcinogens, prior to development of tumor-specific transplantation antigens. [a, l\P or DB[a, Comparison with histological features of contact hypersensitivity reactions. Striking changes were seen in the microscopic anatomy of the skin 2 days after a single application of 200 nmol DB[a,/]P or DB[#,/]P-11,12-dihydrodiol to the shaved skin of the back. These changes were indicative of epidermal cell damage and included (1) marked enlargement of the epidermal cells associated with perinuclear vacuolation, (2) the presence of necrotic keratinocytes, and (3) a predominantly PMNL infiltrate in the dermis. Epidermal damage characterized the skin through Day 4 after skin treatment. During this period, the gross appearance of treated skin was indistinguishable from that of untreated skin. Epidermal damage is viewed as a requirement for the proposed induction of contact hypersensitivity by DB[a,/]P or its 11,12-dihydrodiol. It may serve as a mechanism by which adducted, cisternal proteins of the ER are released from the cell and made accessible to the antigen-processing cells of the skin.
Histological features of mouse skin treated with DB
By Day 5, evidence of epidermal cell damage was significantly diminished and the microscopic anatomy of the skin had changed to a hyperplastic character. Microscopic features on Days 5 through 7 were similar to those seen in human skin expressing a contact hypersensitivity reaction to dinitrochlorobenzene (Dvorak et al., 1974) and were associated with the appearance and progression of dermal erythema. These features included (1) epidermal hyperplasia associated with intercellular edema, (2) thickening of the outermost, cornified layer of the epidermis, (3) engorgement of dermal blood vessels with red cells, and (4) a markedly increased proportion of MNL in the dermis.
Contact hypersensitivity to DB[a,l\P expressed as an earswelling reaction to a secondary challenge with DB[a,t\P.
On the basis of the above observations, mice treated with a single dermal application of DB[a,/]P were tested for contact hypersensitivity expressed as an ear-swelling reaction to the carcinogen. Ear swelling in response to challenge with a skin sensitizer is an established model of contact hypersensitivity in mice (Asherson and Ptak, 1968) . Using this model, Klemme et al. (1987) demonstrated the induction of contact hypersensitivity to both BP and DMBA, in C3H mice. Contact hypersensitivity was evident 5 days after a single application of BP or DMBA to the abdominal skin. At this time, application of the sensitizing agent to the ear induced an ear-swelling reaction with a time course characteristic of delayed hypersensitivity.
In the present study, the ear-swelling reaction to DB[a,/]P exhibited cardinal features of a contact hypersensitivity reaction. First, this reactivity was acquired by prior exposure to DB[a,/]P and was not elicited in animals which had not been previously exposed to the chemical. Second, ear swelling represented a reaction of naive tissue at a site other than the site of initial exposure to the carcinogen. Animals were first treated with DB[a,/]P on the shaved skin of the back, then challenged with a single application to the ear pinna. Third, the time course of this reaction was characteristic of a contact hypersensitivity reaction. Swelling of the ear pinna was delayed for 2 days after challenge with 40 or 80 nmol DB[a,/]P. The reaction appeared with high intensity on Day 3, progressed rapidly to maximum or near maximum intensity, and remained at this level of intensity for the balance of the 9-day observation period. Fourth, the ear-swelling reaction was chemical-specific. Animals initially treated with acetone or DMBA exhibited no significant ear swelling for 4 days after challenge with 80 nmol DB[a,/]P. By Day 5, however, these animals exhibited mild ear swelling that progressed to maximum intensity by Day 7. This response in mice not exposed previously to DB[a,/]P reproduced the time course of dermal erythema after a single application of the carcinogen to the shaved skin of the back. Thus, a single application of DB[a,/]P to the ear pinna of naive mice both induced contact hypersensitivity and elicited a contact hypersensitivity reaction, i.e., ear swelling. Contact hypersensitivity may be induced with a high degree of effectiveness by a single application of chemical sensitizer to the ear pinna of the mouse (Kitagaki et al., 1995) . Features of the ear-swelling reaction in mice previously exposed to DB[a,/]P indicate induction of contact hypersensitivity by the carcinogen.
In summary, DB[a,/]P, the most potent carcinogen among PAH, was shown to be a strong inducer of inflammation in mouse skin. Histological features of this inflammation were consistent with tumor promotion and included epidermal hyperplasia and infiltration of the dermis with leukocytes. The time course of the erythema and the microscopic pathology of the skin after a single application of DB[a,/]P or its 11,12-dihydrodiol suggest an immune mechanism. Evaluation of ear-swelling reactions in mice previously treated with a single application of DB[a,/]P indicated that the carcinogen had induced an immune contact hypersensitivity. It is proposed that the inflammation induced by DB[a,/]P contributes significantly to its carcinogenic activity via tumor promotion. Immune deletion studies aimed at determining the relationship between DB[a,/]P-induced contact hypersensitivity and both dermal erythema and tumor production are now in progress.
